Published in J Med Chem on March 12, 2009
MYC on the path to cancer. Cell (2012) 8.65
Understanding protein non-folding. Biochim Biophys Acta (2010) 4.33
A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol (2010) 1.75
Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol (2010) 1.70
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Assemblages: functional units formed by cellular phase separation. J Cell Biol (2014) 1.30
Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci (2014) 1.16
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget (2013) 1.00
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev Proteomics (2010) 0.93
The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PLoS One (2012) 0.89
Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget (2014) 0.88
Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc. Sci Rep (2016) 0.80
Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion. Oncotarget (2015) 0.80
A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine (Lond) (2015) 0.79
Reviewing ligand-based rational drug design: the search for an ATP synthase inhibitor. Int J Mol Sci (2011) 0.78
A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors. J Biol Methods (2015) 0.77
Target Based Designing of Anthracenone Derivatives as Tubulin Polymerization Inhibiting Agents: 3D QSAR and Docking Approach. Int J Med Chem (2014) 0.75
cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. Cell Cycle (2016) 0.75
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Oncotarget (2015) 0.75
Discovery of Potential Orthosteric and Allosteric Antagonists of P2Y1R from Chinese Herbs by Molecular Simulation Methods. Evid Based Complement Alternat Med (2016) 0.75
Methods of probing the interactions between small molecules and disordered proteins. Cell Mol Life Sci (2017) 0.75
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys (2008) 3.98
Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature (1992) 3.43
Do structurally similar molecules have similar biological activity? J Med Chem (2002) 3.29
The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J (1993) 2.57
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther (2004) 1.42
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
GALAHAD: 1. pharmacophore identification by hypermolecular alignment of ligands in 3D. J Comput Aided Mol Des (2006) 1.36
Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol (2006) 1.35
The human CYP3A subfamily: practical considerations. Drug Metab Rev (2001) 1.26
C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res (2005) 1.19
Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Mol Cancer Ther (2007) 0.98
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J Comb Chem (2006) 0.95
A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches. J Comput Aided Mol Des (2006) 0.94
Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ (1998) 0.93
Integrating Myc and TGF-beta signalling in cell-cycle control. Nat Cell Biol (2001) 0.89
Fragmental methods in the analysis of biological activities of diverse compound sets. Mini Rev Med Chem (2003) 0.86
Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J Chem Inf Model (2006) 0.84
Using a staged multi-objective optimization approach to find selective pharmacophore models. J Comput Aided Mol Des (2008) 0.80
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci U S A (2005) 2.84
Global ribosome motions revealed with elastic network model. J Struct Biol (2004) 2.84
Coupling between catalytic site and collective dynamics: a requirement for mechanochemical activity of enzymes. Structure (2005) 2.75
Dynamics of large proteins through hierarchical levels of coarse-grained structures. J Comput Chem (2002) 2.60
Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57
ProDy: protein dynamics inferred from theory and experiments. Bioinformatics (2011) 2.55
Anisotropic network model: systematic evaluation and a new web interface. Bioinformatics (2006) 2.52
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding. Proc Natl Acad Sci U S A (2009) 2.12
Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn (2009) 2.11
High-efficiency bypass of DNA damage by human DNA polymerase Q. EMBO J (2004) 2.07
Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther (2007) 1.95
Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc (2009) 1.92
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
Prototyping of microfluidic devices in poly(dimethylsiloxane) using solid-object printing. Anal Chem (2002) 1.76
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem (2008) 1.74
Signal propagation in proteins and relation to equilibrium fluctuations. PLoS Comput Biol (2007) 1.67
Insights into equilibrium dynamics of proteins from comparison of NMR and X-ray data with computational predictions. Structure (2007) 1.66
Markov propagation of allosteric effects in biomolecular systems: application to GroEL-GroES. Mol Syst Biol (2006) 1.66
iGNM: a database of protein functional motions based on Gaussian Network Model. Bioinformatics (2005) 1.65
Elastic network models for understanding biomolecular machinery: from enzymes to supramolecular assemblies. Phys Biol (2005) 1.64
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62
Relating molecular flexibility to function: a case study of tubulin. Biophys J (2002) 1.62
Time-resolved mechanism of extracellular gate opening and substrate binding in a glutamate transporter. J Biol Chem (2008) 1.61
oGNM: online computation of structural dynamics using the Gaussian Network Model. Nucleic Acids Res (2006) 1.60
Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene (2005) 1.57
Escherichia coli adenylate kinase dynamics: comparison of elastic network model modes with mode-coupling (15)N-NMR relaxation data. Proteins (2004) 1.55
The interface of protein structure, protein biophysics, and molecular evolution. Protein Sci (2012) 1.54
Allosteric transitions of supramolecular systems explored by network models: application to chaperonin GroEL. PLoS Comput Biol (2009) 1.50
Principal component analysis of native ensembles of biomolecular structures (PCA_NEST): insights into functional dynamics. Bioinformatics (2009) 1.50
Identification of core amino acids stabilizing rhodopsin. Proc Natl Acad Sci U S A (2004) 1.48
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem (2005) 1.40
Common mechanism of pore opening shared by five different potassium channels. Biophys J (2006) 1.40
Maturation dynamics of bacteriophage HK97 capsid. Structure (2005) 1.38
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem (2003) 1.37
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem (2002) 1.37
Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol (2008) 1.34
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem (2005) 1.31
The substrate recognition domains of the N-end rule pathway. J Biol Chem (2008) 1.31
Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene (2005) 1.30
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res (2007) 1.28
Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med (2011) 1.27
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res (2004) 1.26
Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta (2010) 1.25
Coupling between global dynamics and signal transduction pathways: a mechanism of allostery for chaperonin GroEL. Mol Biosyst (2008) 1.24
Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer (2010) 1.23
Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins (2002) 1.23
Fast-folding protein kinetics, hidden intermediates, and the sequential stabilization model. Protein Sci (2002) 1.21
Inflammatory modulation of hepatocyte apoptosis by nitric oxide: in vivo, in vitro, and in silico studies. Curr Mol Med (2004) 1.21
Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem (2002) 1.20
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol (2010) 1.20
Anisotropic fluctuations of amino acids in protein structures: insights from X-ray crystallography and elastic network models. Bioinformatics (2007) 1.20
C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res (2005) 1.19
Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov (2002) 1.19
Mechanism of signal propagation upon retinal isomerization: insights from molecular dynamics simulations of rhodopsin restrained by normal modes. Biophys J (2008) 1.18
Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput (2012) 1.18
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol (2005) 1.18
Functional motions of influenza virus hemagglutinin: a structure-based analytical approach. Biophys J (2002) 1.17
Large collective motions regulate the functional properties of glutamate transporter trimers. Proc Natl Acad Sci U S A (2011) 1.15
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol (2008) 1.14
Sequence evolution correlates with structural dynamics. Mol Biol Evol (2012) 1.14
Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis (2009) 1.14
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene (2005) 1.11
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis (2010) 1.10
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther (2008) 1.10
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol (2010) 1.10
Analysis of correlated mutations in HIV-1 protease using spectral clustering. Bioinformatics (2008) 1.10
Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS One (2012) 1.09
Pre-existing soft modes of motion uniquely defined by native contact topology facilitate ligand binding to proteins. Protein Sci (2011) 1.09
Myc target in myeloid cells-1, a novel c-Myc target, recapitulates multiple c-Myc phenotypes. J Biol Chem (2002) 1.09
Molecular simulations elucidate the substrate translocation pathway in a glutamate transporter. Proc Natl Acad Sci U S A (2009) 1.09
Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials (2006) 1.08
Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One (2013) 1.07
Role of Hsp70 ATPase domain intrinsic dynamics and sequence evolution in enabling its functional interactions with NEFs. PLoS Comput Biol (2010) 1.07
Coupled global and local changes direct substrate translocation by neurotransmitter-sodium symporter ortholog LeuT. Biophys J (2013) 1.07
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol (2007) 1.07
Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product. Chem Biol Drug Des (2006) 1.05
Dynamics and allosteric potential of the AMPA receptor N-terminal domain. EMBO J (2011) 1.05
Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol (2013) 1.05
Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget (2012) 1.04